Vivani Medical Share Holder Equity 2013-2024 | VANI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vivani Medical share holder equity from 2013 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vivani Medical share holder equity from 2013 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$80.4B
Zoetis (ZTS)	$70.5B
Takeda Pharmaceutical (TAK)	$44.1B
Daiichi Sankyo, - (DSNKY)	$43.3B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$18.5B
Astellas Pharma (ALPMY)	$17.5B
Summit Therapeutics (SMMT)	$17B
United Therapeutics (UTHR)	$16.4B
Shionogi (SGIOY)	$12.3B
Neurocrine Biosciences (NBIX)	$11.6B
Orion OYJ (ORINY)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Corcept Therapeutics (CORT)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Stevanato Group S.p.A (STVN)	$6.2B
Ionis Pharmaceuticals (IONS)	$5.2B
Grifols, S.A (GRFS)	$5.2B
Ono Pharmaceutical (OPHLF)	$4.7B
Recursion Pharmaceuticals (RXRX)	$4B
Crinetics Pharmaceuticals (CRNX)	$3.4B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.2B
Hypermarcas (HYPMY)	$2.2B
Soleno Therapeutics (SLNO)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.8B
Evotec AG (EVO)	$1.6B
Dyne Therapeutics (DYN)	$1.4B